



IPW

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/829,137	
	Filing Date	April 21, 2004
	First Named Inventor	Gevas et al.
	Art Unit	unassigned
	Examiner Name	unassigned
Attorney Docket Number	ACG2BUSA	
Total Number of Pages in This Submission	15	

### ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please Identify below):
<b>Remarks</b>  Customer No. 00270		

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	HOWSON AND HOWSON Mary E. Bak
Signature	<i>Mary E. Bak</i>
Date	June 30, 2004

### CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Kelly A. Karstaedt		
Signature	<i>Kelly A. Karstaedt</i>	Date	June 30, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



ACG2BUSA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No. : 10/829,137 Confirmation No.: unassigned  
Applicant : Gevas et al.  
Filed : April 21, 2004  
TC/A.U. : unassigned  
Examiner : unassigned  
Customer No. : 00270  
Title : PREVENTION AND TREATMENT OF  
HYPERGASTRINEMIA

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Applicants submit to the Examiner the attached Form PTO/SB/08A/B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08A/B and this paper identify documents previously cited in US Patent Application No. 09/700,329, filed February 8, 2001. Copies of documents BF and BBZ are attached.

According to 37 CFR § 1.98(d), Applicants have not enclosed copies of any US patents, publications, or other documents listed herein, which listed items were previously cited by or submitted to the US Patent and Trademark Office in prior parent

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date: June 30, 2004  
Signature Kelly A. Karstaedt  
Name Kelly A. Karstaedt

US Patent Application No. 09/700,329, filed February 8, 2001. The prior parent application is relied upon herein for an earlier priority date under 35 USC § 120.

This Information Disclosure Statement is submitted less than three months from the filing date of this application and before the receipt of a first Office Action. Therefore, no fees are believed due.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

### REMARKS

Listed below are previously filed, and co-pending, US Patent applications. These applications and the present application are commonly owned:

- (a) U.S. Patent Application No. 10/314,057, filed December 6, 2002,  
U.S. Patent Publication No. US-2003-0068326-A1, published April 10,  
2003 (item BI)
- (b) U.S. Patent Application No. 09/700,329, filed February 8, 2001

Listed below are documents cited in the International Search Report dated October 19, 1999 in the corresponding International Patent Publication No. WO-99/59631, published November 25, 1999. A copy of the Report is enclosed.

- (a) THORNDYKE et al., "Identification and localization of material with gastrin-like immunoreactivity in the neural ganglion of a protochordate, *Ciona intestinalis*", *Regulatory Peptides* **1986** 16:269-279
- (b) WATSON et al., "Gastrimmune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer", *Cancer Res.* **February 15, 1996** 56:880-885
- (c) WATSON et al., "Anti-gastrin antibodies raised by gastrimmune inhibit growth of the human colorectal tumour AP5", *Int. J. Cancer* **1995** 61:233-240
- (d) U.S. Patent No. 5,023,077, issued June 11, 1991
- (e) U.S. Patent No. 5,468,494, issued November 21, 1995

- (f) U.S. Patent No. 5,609,870, issued March 11, 1997
- (g) U.S. Patent No. 5,607,676, issued March 4, 1997
- (h) U.S. Patent No. 5,622,702, issued April 22, 1997

Listed below are documents cited in the International Search Report dated August 24, 1999 in the related International Patent Publication No. WO-99/59612, published November 25, 1999. A copy of the Report is enclosed.

- (a) U.S. Patent No. 5,468,494, issued November 21, 1995
- (b) U.S. Patent No. 5,609,870, issued March 11, 1997
- (c) U.S. Patent No. 5,023,077, issued June 11, 1991
- (d) BUDAVARI et al., The Merck Index (11th ed.), Rahway, New Jersey, Merck & Co., 1989, p. 1082

Listed below are documents cited in the Supplementary European Search Report dated January 22, 2003 in the related European Patent Application No. 99924252.2, filed May 14, 1999.

- (a) HALTER et al., "Evaluation of a monoclonal anti-gastrin antibody as a tool for immunoneutralization of gastrin during omeprazole in treatment in a rat", *Gastroenterology* 1989 96(5):A194 [Abstract]

The month of publication for documents AAR, AAZ, BY, BZ, BBS, CV, CZ, CCR, CCS, CCX, DS, DX, EV, EW, EX, and EY could not be determined. The years of publication for these documents are sufficiently earlier than the effective US filing date and/or the foreign priority date of the present application so that the particular month of publication of the documents is not an issue (MPEP 609).

The Examiner is respectfully requested to consider the enclosed documents identified in this paper and in the attached Form PTO/SB/08A/B during the course of examination of this application.

Respectfully submitted,

HOWSON AND HOWSON  
Attorneys for Applicants

By Mary E. Bak  
Mary E. Bak  
Registration No. 31,215  
Spring House Corporate Center  
Box 457  
Spring House, PA 19477  
Telephone: (215) 540-9200  
Telefacsimile: (215) 540-5818



PTO/SB/08B (08-03)  
Approved for use through 7/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/829,137
				Filing Date	April 21, 2004
				First Named Inventor	Gevas et al.
				Group Art Unit	unassigned
				Examiner Name	unassigned
Sheet	1	of	10	Attorney Docket Number	ACG2BUSA

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	US-3,931,141	01-06-1976	Wissmann	
	AB	US-4,069,313	01-17-1978	Woodhour	
	AC	US-4,201,770	05-06-1980	Stevens	
	AD	US-4,384,995	05-24-1983	Stevens	
	AE	US-4,526,716	07-02-1985	Stevens	
	AF	US-4,565,805	01-21-1986	Smirnov	
	AG	US-4,687,759	08-18-1987	Martinez	
	AH	US-4,691,006	09-01-1987	Stevens	
	AI	US-4,894,443	01-16-1990	Greenfield	
	AJ	US-5,023,077	06-11-1991	Gevas	
	AK	US-5,120,829	06-09-1992	Pierschbacher	
	BA	US-5,256,542	10-26-1993	Chang	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	AL	EP-380 230	08-01-1990	Gevas		
	AM	WO-97/28821	08-14-1997	Gevas		
	AN	WO-99/59628	11-25-1999	Gevas		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.  
**SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

-Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/829,137
				Filing Date	April 21, 2004
				First Named Inventor	Gevas et al.
				Group Art Unit	unassigned
				Examiner Name	unassigned
Sheet	2	of	10	Attorney Docket Number	ACG2BUSA

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	BB	US-5,468,494	11-21-1995	Gevas	
	BC	US-5,607,676	03-04-1997	Gevas	
	BD	US-5,609,870	03-11-1997	Gevas	
	BE	US-5,622,702	04-22-1997	Gevas	
	BF	US-5,668,117	09-16-1997	Shapiro	
	BG	US-5,785,970	07-28-1998	Gevas	
	BH	US-5,866,128	02-02-1999	Gevas	
	BI	US-2003-0068326-A1	04-10-2003	Gevas	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.  
**SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

- Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/829,137
				Filing Date	April 21, 2004
				First Named Inventor	Gevas et al.
				Group Art Unit	unassigned
				Examiner Name	unassigned
Sheet	3	of	10	Attorney Docket Number	ACG2BUSA

NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AR	ANTONSON et al., "High doses of histamine antagonists do not prevent relapses of peptic esophagitis following therapy with a proton pump inhibitor", <i>Gastroenterology</i> May 1990 98(5/2):A16 [Abstract]	
	AS	ARCHAMBAULT et al., "Influence of immunomodulatory agents on bovine humoral and cellular immune responses to parenteral inoculation with bovine rotavirus vaccines", <i>Vet. Microbiol.</i> August 1988 17:323-334	
	AT	AZUMA et al., "Immunocytochemical evidence for differential distribution of gastrin forms using region-specific monoclonal antibodies", <i>Gastroenterologica Japonica</i> August 1986 21(4):319-324	
	AU	BARDHAN et al., "The safety of long-term cimetidine treatment", <i>Gastroenterology</i> May 1990 98(5/2):A18 [Abstract]	
	AV	BEACHAM et al., "Structures of human gastrins I and II", <i>Nature</i> February 1966 209(5023):583-586	
	AW	BEAUCHAMP et al., "Proglumide, a gastrin receptor antagonist, inhibits growth of colon cancer and enhances survival in mice", <i>Ann. Surg.</i> September 1985 202(3):303-309	
	AX	BOOTH et al., "Acid clearing from the distal esophagus", <i>Arch. Surg.</i> May 1968 96:731-734	
	AY	BOWIE et al., "Deciphering the message in protein sequences: Tolerance to amino acid substitutions", <i>Science</i> March 1990 247:1306-1310	
	AZ	BRINTON et al., "Cancer risk following pernicious anaemia", <i>Br. J. Cancer</i> May 1989 59(5):810-813	
	AAR	BUDAVARI et al., The Merck Index (11th ed.), Rahway, New Jersey, Merck & Co., 1989 p. 1082	

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

- Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/829,137
				Filing Date	April 21, 2004
				First Named Inventor	Gevas et al.
				Group Art Unit	unassigned
				Examiner Name	unassigned
Sheet	4	of	10	Attorney Docket Number	ACG2BUSA

NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AAS	CHOUDHURY et al., "N-Terminal sequence of human big gastrin: Sequence, synthetic and immunochemical studies", <i>A76Hoppe-Seyler's Z. Physiol. Chem.</i> <b>November 1980</b> 361:1719-1733	
	AAT	CUNNINGHAM et al., "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis", <i>Science</i> <b>June 1989</b> 244:1081-1085	
	AAU	DE MAGISTRIS et al., "A simple enzymatic procedure for radioimmunochemical quantitation of the large molecular forms of gastrin and cholecystokinin", <i>Analytical Biochem.</i> <b>February 1980</b> 102:126-133	
	AAV	DEMEESTER et al., "Patterns of gastroesophageal reflux in health and disease", <i>Ann. Surg.</i> <b>October 1976</b> 184(4):459-470	
	AAW	DEVAULT et al., "Current diagnosis and treatment of gastroesophageal reflux disease", <i>Mayo Clin. Proc.</i> <b>September 1994</b> 69(9):867-876	
	AAX	DOCKRAY et al., "Amino terminal gastrin fragment in serum of Zollinger-Ellison syndrome patients", <i>Gastroenterology</i> <b>February 1975</b> 68(2):222-230	
	AAZ	DOCKRAY et al., "Heptadecapeptide gastrin: measurement in blood by specific radioimmunoassay", <i>Gastroenterology</i> <b>December 1976</b> 71(6):971-977	
	AAZ	DOCKRAY et al., "Immunochemical studies on big gastrin using NH <sub>2</sub> -terminal specific antisera", <i>Chemical Abstracts</i> <b>1981</b> 94:506-507 [Abstract# 94:119200w]	
	BR	DOCKRAY, G., "Immunochemical studies on big gastrin using NH <sub>2</sub> -terminal specific antisera", <i>Regulatory Peptides</i> <b>December 1980</b> 1:169-186	
	BS	FENNERTY et al., "Medical therapy for gastroesophageal reflux disease", <i>Arch. Intern. Med.</i> <b>December 1991</b> 151(12):2365-2366	
	BT	FESTEN et al., "Effect of oral omeprazole on serum gastrin and serum pepsinogen I levels", <i>Gastroenterology</i> <b>November 1984</b> 87(5):1030-1034	

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

-Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/829,137
				Filing Date	April 21, 2004
				First Named Inventor	Gevas et al.
				Group Art Unit	unassigned
				Examiner Name	unassigned
Sheet	5	of	10	Attorney Docket Number	ACG2BUSA

## NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	BU	FLYNN et al., "Modulation of T-cell reactivity to synthetic peptide analogues of foot-and-mouth disease virus in sheep by amino acid substitutions", <i>Vet. Immunol. Immunopath.</i> <b>March 1992</b> 31:255-266	
	BV	FRESTON et al., "Long-term acid control and proton pump inhibitors: interactions and safety issues in perspective", <i>Am. J. Gastroenterol.</i> <b>April 1997</b> 92(4):51S-57S [Supplement]	
	BW	GEVAS et al., "Prevention and treatment of hypergastrinemia", <i>U.S. Patent App. No. 09/700,329</i> , filed <b>February 8, 2001</b>	
	BX	GREGORY et al., "Isolation of two gastrins from human antral mucosa", <i>Nature</i> <b>February 1966</b> 209(5023):583	
	BY	HALTER et al., "Evaluation of a monoclonal anti-gastrin antibody as a tool for immunoneutralization of gastrin during omeprazole in treatment in a rat", <i>Gastroenterology</i> <b>1989</b> 96(5):A194 [Abstract]	
	BZ	HOUGHTEN et al., "Relative importance of position and individual amino acid residues in peptide antigen-antibody interactions: Implications in the mechanism of antigenic drift and antigenic shift", <i>Vaccines</i> 86 (Ed. F. Brown et al.) <b>1986</b> Cold Spring Harbor Laboratory: 21-25	
	BBR	HUGHES et al., "Therapy with gastrin antibody in the Zollinger-Ellison Syndrome", <i>Digestive Disease</i> <b>March 1976</b> 21(3):201-204	
	BBS	IWANAGA et al., "Immunocytochemical localization of the different gastrin forms in the pyloric antrum", <i>Biomed. Res.</i> <b>1980</b> 1:316-320	
	BBT	JAFFE et al., "Gastrin resistance following immunization to the C-terminal tetrapeptide amide of gastrin", <i>Surgery</i> <b>February 1971</b> 69(2):232-237	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

-Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/829,137
				Filing Date	April 21, 2004
				First Named Inventor	Gevas et al.
				Group Art Unit	unassigned
				Examiner Name	unassigned
Sheet	6	of	10	Attorney Docket Number	ACG2BUSA

**NONPATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	BBU	JAFFE et al., "Inhibition of endogenous gastrin activity by antibodies to the carboxyl-terminal tetrapeptide amide of gastrin", <i>Gastroenterology</i> <b>February 1970</b> 58(2):151-156	
	BBV	JAFFE et al., "Inhibition of gastrin activity by incubation with antibodies to the C-terminal tetrapeptide of gastrin", <i>Surgery</i> <b>April 1969</b> 65(4):633-639	
	BBW	JANSEN et al., "Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis", <i>Gastroenterology</i> <b>September 1990</b> 99(3):621-628	
	BBX	JONES et al., "Peptide vaccines derived from a malarial surface antigen: effects of dose and adjuvants on immunogenicity", <i>Immunology Letters</i> <b>July 1990</b> 24:253-260	
	BBY	KOTHARY et al., "NH2-terminal of gastrin-17 in duodenal ulcer disease: Identification of progastrin-17", <i>Biochem. Biophys. Res. Comm.</i> <b>July 1987</b> 146(2):884-888	
	BBZ	KUIPERS et al., "Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication", <i>New. Eng. J. Med.</i> <b>April 1996</b> 334(16):1018-1022	
	CR	KUSYK et al., "Stimulation of growth of a colon cancer cell line by gastrin", <i>Am. J. Physiol.</i> <b>November 1986</b> 251:G597-G601	
	CS	LAMERS et al., "Role of gastrin and cholecystikinin in tumors of the gastrointestinal tract", <i>Eur. J. Cancer Clin. Oncol.</i> <b>February 1988</b> 24(2):267-273	
	CT	LAMOTE et al., "Stimulating effect of pentagastrin on cancer cell proliferation kinetics in chemically induced colon cancer in rats", <i>Regulatory Peptides</i> <b>January 1988</b> 20:1-9	
	CU	LARSSON et al., "Characterization of antral gastrin cells with region-specific antisera", <i>J. histochem. Cytochem.</i> <b>December 1977</b> 25(12):1317-1321	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

•Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/829,137
				Filing Date	April 21, 2004
				First Named Inventor	Gevas et al.
				Group Art Unit	unassigned
				Examiner Name	unassigned
Sheet	7	of	10	Attorney Docket Number	ACG2BUSA

NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	CV	LARSSON, L, "Histochemistry of gastrin cells", <i>Neurohistochem.: Modern Meth. And App.</i> <b>1986</b> Alan R. Liss, Inc.: 527-567	
	CW	MAKISHIMA et al., "Active immunization against gastrin-17 with an N-terminal derived immunogen inhibits gastric and duodenal lesions in rats", <i>Gastroenterology</i> <b>April 1994</b> 106(4/2):A824 [Abstract]	
	CX	MCCLOY et al., "Pathophysiological effects of long-term acid suppression in man", <i>Dig. Dis. And Sciences</i> <b>February 1995</b> 40(2):96S-120S [Supplement]	
	CY	MCGREGOR et al., "Trophic effects of gastrin on colorectal neoplasms in the rat", <i>Ann. Surg.</i> <b>February 1982</b> 195(2):219-223	
	CZ	MORODER et al., "Gastrins and cholecystokinins: Chemical and immunological aspects", <i>Gastrin and Cholecystokinins, Chem., Physio. And Pharma.</i> (Ed. J. Bali et al.) <b>1987</b> Elsevier Science Publishers B.V.: 21-32	
	CCR	NEMETH et al., "A gastrin aminoterminalis 1-13 fragmensevel kidolgozott, szekvenciaspecifikus radioimmunoassay", <i>Izotoptechnika</i> <b>1982</b> 25(4):288-294	
	CCS	NEMETH et al., "Development of a sequence-specific radioimmunoassay by using N-terminal gastrin 1-13 antibody", <i>Chemical Abstracts</i> <b>1983</b> 98:495 [Abstract# 98:51653w]	
	CCT	PALMER SMITH et al., "Effects of gastrin, proglumide, and somatostatin on growth of human colon cancer", <i>Gastroenterology</i> <b>December 1988</b> 95(6):1541-1548	
	CCU	PALMER SMITH et al., "Elevated gastrin levels in patients with colon cancer or adenomatous polyps", <i>Dig. Diseases. And Sci.</i> <b>February 1989</b> 34(2):171-174	
	CCV	PAWLIKOWSKI et al., "Gastrin and somatostatin levels in patients with gastric cancer", <i>Horm. Metabol. Res.</i> <b>February 1989</b> 21:89-91	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

*Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/829,137
				Filing Date	April 21, 2004
				First Named Inventor	Gevas et al.
				Group Art Unit	unassigned
				Examiner Name	unassigned
Sheet	8	of	10	Attorney Docket Number	ACG2BUSA

NONPATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T <sup>2</sup>
	CCW	POWER et al., "A novel gastrin-processing pathway in mammalian antrum", <i>Chemical Abstracts</i> <b>August 1988</b> 109(9):113 [Abstract# 109:67341z]		
	CCX	RAE-VENTER et al., "Gastrin receptors in human colon carcinoma", <i>Gastroenterology</i> <b>1986</b> 80(5/2):1256 [Abstract]		
	CCY	REHFELD et al., "Production and evaluation of antibodies for the radioimmunoassay of gastrin", <i>Scand. J. Clin. Lab. Invest.</i> <b>October 1972</b> 30:221-232		
	CCZ	REHFELD et al., "Sulfation of gastrin: Effect on immunoreactivity", <i>Regulatory Peptides</i> <b>September 1981</b> 2:333-342		
	DR	SABESIN et al., "Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations", <i>Arch. Intern. Med.</i> <b>December 1991</b> 151(12):2394-2400		
	DS	SIEMANN, D., "Satisfactory and unsatisfactory tumor models: Factors influencing the selection of a tumor model for experimental evaluation", <i>Rodent Tumor Models in Experimental Cancer Therapy</i> (Ed. Kallman) <b>1987</b> Pergamon Press, NY: 12-15		
	DT	SOBHANI et al., "Chronic endogenous hypergastrinemia in humans: Evidence for a mitogenic effect on the colonic mucosa", <i>Gastroenterology</i> <b>July 1993</b> 105(1):22-30		
	DU	SONTAG et al., "Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: The US Multicenter Study", <i>Gastroenterology</i> <b>January 1992</b> 102(1):109-118		
	DV	SUGANO et al., "Identification and characterization of glycine-extended post-translational processing intermediates of progastrin in porcine stomach", <i>J. Bio. Chem.</i> <b>September 1986</b> 260(21):11724-11729		
	DW	SUMII et al., "Regulation of antral peptides by administration of omeprazole to healthy men", <i>Am. J. Gastroenterol.</i> <b>November 1994</b> 89(11):2033-2037		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/829,137
				Filing Date	April 21, 2004
				First Named Inventor	Gevas et al.
				Group Art Unit	unassigned
				Examiner Name	unassigned
Sheet	9	of	10	Attorney Docket Number	ACG2BUSA

## NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	DX	SUNDLER et al., "The neuroendocrine system of the gut--an update", <i>Acta Oncologica</i> <b>1991</b> 30(4):419-427	
	DY	TALLEY et al., "Risk for colorectal adenocarcinoma in pernicious anemia", <i>Annals of Internal Medicine</i> <b>November 1989</b> 111(9):738-742	
	DZ	THORNDYKE et al., "Identification and localization of material with gastrin-like immunoreactivity in the neural ganglion of a protochordate, <i>Ciona intestinalis</i> ", <i>Regulatory Peptides</i> <b>December 30, 1986</b> 16:269-279	
	DDR	TIELEMANS et al., "Proliferation of enterochromaffinlike cells in omeprazole-treated hypergastrinemic rats", <i>Gastroenterology</i> <b>March 1989</b> 96(3):723-729	
	DDS	UPP et al., "Clinical significance of gastrin receptors in human colon cancers", <i>Cancer Res.</i> <b>January 1989</b> 49:488-492	
	DDT	UPP et al., "Polyamine levels and gastrin receptors in colon cancers", <i>Ann. Surg.</i> <b>June 1988</b> 207(6):662-669	
	DDU	VARNDELL et al., "Intracellular topography of immunoreactive gastrin demonstrated using electron immunocytochemistry", <i>Experientia</i> <b>July 15, 1983</b> 39:713-717	
	DDV	VARRO et al., "Pathways of processing of the gastrin precursor in rat antral mucosa", <i>J. Clin. Invest.</i> <b>April 1995</b> 95:1642-1649	
	DDW	WANG et al., "Processing and proliferative effects of human progastrin in transgenic mice", <i>J. Clin. Invest.</i> <b>October 1996</b> 98(8):1918-1929	
	DDX	WATSON et al., "Anti-gastrin antibodies raised by gastrimmune inhibit growth of the human colorectal tumour AP5", <i>Int. J. Cancer</i> <b>April 10, 1995</b> 61:233-240	
	DDY	WATSON et al., "Gastrimmune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer", <i>Cancer Res.</i> <b>February 15, 1996</b> 56:880-885	

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/829,137
				Filing Date	April 21, 2004
				First Named Inventor	Gevas et al.
				Group Art Unit	unassigned
				Examiner Name	unassigned
Sheet	10	of	10	Attorney Docket Number	ACG2BUSA

**NONPATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	DDZ	WATSON et al., "Growth-promoting action of gastrin on human colonic and gastric tumour cells cultured in vitro", <i>Br. J. Surg.</i> <b>April 1988</b> 75(4):342-345 [Abstract]	
	ER	WATSON et al., "Pre-clinical evaluation of the gastrimmune immunogen alone and in combination with 5-fluorouracil/leucovorin in a rat colorectal cancer model", <i>Int. J. Cancer</i> <b>March 16, 1998</b> 75:873-877	
	ES	WEINSTOCK et al., "Binding of gastrin(17) to human gastric carcinoma cell lines", <i>Cancer Res.</i> <b>February 1988</b> 48(4):932-937 [Abstract]	
	ET	WENDLBERGER et al., "The syntheses of human big gastrin I and its 32-leucine analog", <i>Chemical Abstracts</i> <b>May 1980</b> 92(21):722 [Abstract# 92:198749s]	
	EU	WUNSCH et al., "Biological and immunological properties of human gastrin I analogues", <i>Hoppe-Syler's Z. Physiol. Chem.</i> <b>June 1982</b> 363:665-669	
	EV	YAMAGUCHI et al., "Amino-terminal immunoreactivity of big gastrin in plasma and tumors obtained from patients with Zollinger-Ellison Syndrome", <i>Chem. Abstracts</i> <b>1984</b> 100:373 [Abstract# 100:154661m]	
	EW	YANAIHARA et al., "A new type of gastrin derivative and its use for production of central region-specific anti-gastrin sera", <i>Biomedical Research</i> <b>1980</b> 1:242-247	
	EX	YANAIHARA et al., "Human big gastrin N-terminal fragment immunoreactivity", <i>Gut Peptides</i> (Ed. A. Miyoshi) <b>1979</b> Elsevier/North-Holland Biomedical Press: 26-33	
	EY	ZEITOUN, P., "Comparison of omeprazole with ranitidine in the treatment of reflux oesophagitis", <i>Scand. J. Gastroenterol.</i> <b>1989</b> 166:83-87	

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.